Literature DB >> 21139082

Deregulation of Aiolos expression in chronic lymphocytic leukemia is associated with epigenetic modifications.

Katy Billot1, Jérémie Soeur, Fanny Chereau, Issam Arrouss, Hélène Merle-Béral, Meng-Er Huang, Dominique Mazier, Véronique Baud, Angelita Rebollo.   

Abstract

Chronic lymphocytic leukemia (CLL) is characterized by a clonal accumulation of mature neoplastic B cells that are resistant to apoptosis. Aiolos, a member of the Ikaros family of zinc-finger transcription factors, plays an important role in the control of mature B lymphocyte differentiation and maturation. In this study, we showed that Aiolos expression is up-regulated in B-CLL cells. This overexpression does not implicate isoform imbalance or disturb Aiolos subcellular localization. The chromatin status at the Aiolos promoter in CLL is defined by the demethylation of DNA and an enrichment of euchromatin associated histone markers, such as the dimethylation of the lysine 4 on histone H3. These epigenetic modifications should allow its upstream effectors, such as nuclear factor-κB, constitutively activated in CLL, to gain access to promoter, resulting up-regulation of Aiolos. To determine the consequences of Aiolos deregulation in CLL, we analyzed the effects of Aiolos overexpression or down-regulation on apoptosis. Aiolos is involved in cell survival by regulating the expression of some Bcl-2 family members. Our results strongly suggest that Aiolos deregulation by epigenetic modifications may be a hallmark of CLL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21139082     DOI: 10.1182/blood-2010-09-307140

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  Uncovering the DNA methylome in chronic lymphocytic leukemia.

Authors:  Nicola Cahill; Richard Rosenquist
Journal:  Epigenetics       Date:  2013-01-15       Impact factor: 4.528

2.  Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance).

Authors:  John C Byrd; Amy S Ruppert; Nyla A Heerema; Alese E Halvorson; Eva Hoke; Mitchell R Smith; John E Godwin; Stephen Couban; Todd A Fehniger; Michael J Thirman; Martin S Tallman; Frederick R Appelbaum; Richard M Stone; Sue Robinson; Julie E Chang; Sumithra J Mandrekar; Richard A Larson
Journal:  Blood Adv       Date:  2018-07-24

3.  Aiolos promotes anchorage independence by silencing p66Shc transcription in cancer cells.

Authors:  Xichuan Li; Zhao Xu; Wei Du; Zhenfa Zhang; Yiliang Wei; Hao Wang; Zhiyan Zhu; Litao Qin; Lin Wang; Qing Niu; Xiulan Zhao; Luc Girard; Yimei Gong; Zhenyi Ma; Baocun Sun; Zhi Yao; John D Minna; Lance S Terada; Zhe Liu
Journal:  Cancer Cell       Date:  2014-05-12       Impact factor: 31.743

Review 4.  Chronic lymphocytic leukaemia: could immunological tolerance mechanisms be the origin of lymphoid neoplasms?

Authors:  Ricardo García-Muñoz; Luis Llorente
Journal:  Immunology       Date:  2014-08       Impact factor: 7.397

5.  Mutations driving CLL and their evolution in progression and relapse.

Authors:  Dan A Landau; Eugen Tausch; Amaro N Taylor-Weiner; Chip Stewart; Johannes G Reiter; Jasmin Bahlo; Sandra Kluth; Ivana Bozic; Mike Lawrence; Sebastian Böttcher; Scott L Carter; Kristian Cibulskis; Daniel Mertens; Carrie L Sougnez; Mara Rosenberg; Julian M Hess; Jennifer Edelmann; Sabrina Kless; Michael Kneba; Matthias Ritgen; Anna Fink; Kirsten Fischer; Stacey Gabriel; Eric S Lander; Martin A Nowak; Hartmut Döhner; Michael Hallek; Donna Neuberg; Gad Getz; Stephan Stilgenbauer; Catherine J Wu
Journal:  Nature       Date:  2015-10-14       Impact factor: 49.962

6.  Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups.

Authors:  A Burns; R Alsolami; J Becq; B Stamatopoulos; A Timbs; D Bruce; P Robbe; D Vavoulis; R Clifford; M Cabes; H Dreau; J Taylor; S J L Knight; R Mansson; D Bentley; R Beekman; J I Martín-Subero; E Campo; R S Houlston; K E Ridout; A Schuh
Journal:  Leukemia       Date:  2017-06-06       Impact factor: 11.528

7.  Epstein-Barr Virus BART Long Non-coding RNAs Function as Epigenetic Modulators in Nasopharyngeal Carcinoma.

Authors:  Rob J A Verhoeven; Shuang Tong; Bobo Wing-Yee Mok; Jiayan Liu; Songtao He; Jingfeng Zong; Yixin Chen; Sai-Wah Tsao; Maria Li Lung; Honglin Chen
Journal:  Front Oncol       Date:  2019-10-22       Impact factor: 6.244

8.  A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation.

Authors:  Gregory Lazarian; Shanye Yin; Elisa Ten Hacken; Tomasz Sewastianik; Mohamed Uduman; Alba Font-Tello; Satyen H Gohil; Shuqiang Li; Ekaterina Kim; Heather Joyal; Leah Billington; Elizabeth Witten; Mei Zheng; Teddy Huang; Mariano Severgnini; Valerie Lefebvre; Laura Z Rassenti; Catherine Gutierrez; Katia Georgopoulos; Christopher J Ott; Lili Wang; Thomas J Kipps; Jan A Burger; Kenneth J Livak; Donna S Neuberg; Fanny Baran-Marszak; Florence Cymbalista; Ruben D Carrasco; Catherine J Wu
Journal:  Cancer Cell       Date:  2021-03-08       Impact factor: 31.743

9.  A novel, non-canonical splice variant of the Ikaros gene is aberrantly expressed in B-cell lymphoproliferative disorders.

Authors:  Daria Capece; Francesca Zazzeroni; Maria Michela Mancarelli; Daniela Verzella; Mariafausta Fischietti; Ambra Di Tommaso; Rita Maccarone; Sara Plebani; Mauro Di Ianni; Alberto Gulino; Edoardo Alesse
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

10.  Effect of Notch and PARP Pathways' Inhibition in Leukemic Cells.

Authors:  Luka Horvat; Mariastefania Antica; Maja Matulić
Journal:  Cells       Date:  2018-06-14       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.